October 18, 2017 / 10:25 PM / a month ago

BRIEF-FDA approves Gilead's CAR-T cell therapy

Oct 18 (Reuters) - U.S. Food and Drug Administration -

* FDA approves CAR-T cell therapy to treat adults with certain types of large B-cell lymphoma

* FDA says granted approval of Yescarta to Kite Pharma Inc

* FDA says Yescarta carries a boxed warning for Cytokine release syndrome‍​

* FDA says due to risk of CRS and neurologic toxicities, Yescarta is being approved with risk evaluation and mitigation strategy

* FDA says it is requiring that hospitals and their associated clinics that dispense Yescarta be specially certified Source text : (bit.ly/2xPe0Xb) Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below